No Cost Hikes From New Hampshire Insurance Law

20 April 1997

No overall cost increases were reported as a result of a 1995 NewHampshire, USA, law requiring equal health insurance coverage for severe mental illnesses, according to a survey of the state's insurance providers released by the National Alliance for the Mentally Ill.

Despite the claims that the law would cause premiums to skyrocket, the companies reported no change at all due to parity, it was noted. The law required insurers to provide benefits for the treatment and diagnosis of certain biologically-based mental illnesses under the same terms and conditions, and which are not less extensive than, coverage provided for any other type of health care for physical illness.

The survey's questions dealt with use of services, costs, premiums and the extent to which mental health parity was an issue in negotiations with employers, or was a complaint from employers and customers. The parity law was found not to have been a factor in negotiating premiums or benefits with employers. Moreover, no carrier or health plan reported concerns expressed by either employers or consumers relating to the implementation of the new legislation.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight